Prateek Sharma, MD, FASGE reviewing Mayerhofer C, et al. Clin Gastroenterol Hepatol 2023 Jan 30.

There are several elimination diet regimens available, including the 6-food, 4-food, one-food, and targeted elimination diets. This systematic review of 34 studies aimed to determine whether any of these dietary regimens can be effective treatment options for eosinophilic esophagitis.

Douglas K. Rex, MD, MASGE reviewing Dominitz JA. Gastrointest Endosc 2023 Mar 12.

A key part of endoscopic procedures is photographic documentation of what a colonoscopist sees or performs during a procedure. This article from an expert colonoscopist details appropriate photographic documentation during colonoscopy.

Douglas K. Rex, MD, MASGE reviewing Calderwood AH, et al. JAMA Intern Med 2023 Mar 13.

Colonoscopists are advised to consider age, comorbidities, and colonoscopy findings before recommending surveillance. In a study of the New Hampshire Colonoscopy Registry, nearly 10,000 adults older than 65 years undergoing surveillance colonoscopy were evaluated according to colonoscopy findings, recommendations for surveillance, and life expectancy.

Douglas K. Rex, MD, MASGE reviewing Bi D, et al. Gastrointest Endosc 2023 Mar 6.

X-Tack is a through-the-scope suturing device that can be an alternative to through-the-scope clips. No controlled trial of X-Tack versus clips has been reported. In an uncontrolled observational study, patients in 13 U.S. centers were treated with X-Tack to determine its efficacy for the closure of colonic and endoscopic mucosal resection defects.

David A. Schwartz, MD reviewing Friedberg S, et al. Clin Gastroenterol Hepatol 2023 Mar 8.

Upadacitinib was recently approved for the treatment of anti-tumor necrosis factor-refractory moderate to severe ulcerative colitis. Studies investigating its use in Crohn’s disease (CD) have recently been completed and demonstrate efficacy in this population as well. It is currently undergoing review by the U.S. Food and Drug Administration for use in moderate to severe CD. These authors report their real-word experience with upadacitinib in patients with active inflammatory bowel disease.